Kairos Pharma, LTD. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kairos Pharma (market cap ~$6.9M) entered an Investigator-Initiated Research (IIR) agreement with Bayer HealthCare Pharmaceuticals dated July 16, 2026, to conduct a preclinical study combining Bayer's XOFIGO (radium-223 dichloride) with Kairos's lead candidate ENV-105 (carotuximab) in metastatic castration-resistant prostate cancer with bone metastasis. Study runs June–December 2026 with report due January 2027. Kairos retains ownership of study results but grants Bayer a non-exclusive, perpetual, royalty-free license to all data; Bayer holds a 3-month exclusive option to negotiate a license to study data and patent rights. No financial terms disclosed; agreement is standard IIR format with typical liability caps ($1,000/year) and confidentiality provisions (10-year post-term). Principal Investigator: Neil Bhowmick, PhD (Kairos CSO).
Why this rating
Strategic validation from Tier-1 pharma partner; meaningful for $6.9M-market-cap biotech. Bayer's XOFIGO is FDA-approved $570M–$1.3B market; Kairos ENV-105 showed 86% clinical benefit in Phase 2. De-risking for small company; potential to accelerate clinical pathway but no upfront payment or guaranteed commercialization disclosed.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.